REG - Eco Animal Health Gp - Posting of Annual Report and Notice of AGM

ECO Animal HealthAnnouncement

28/08/2025 08:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250828:nRSb0258Xa&default-theme=true

RNS Number : 0258X  Eco Animal Health Group PLC  28 August 2025

28 August 2025

ECO Animal Health Group plc

("ECO" or the "Company")

 

Posting of Annual Report and Notice of AGM

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health
company with a portfolio of marketed veterinary products and a maturing
proprietary R&D pipeline, announces that its Annual Report and Accounts
for the year ended 31 March 2025 ("Annual Report"), Notice of Annual General
Meeting ("AGM") and Form of Proxy have today been posted to shareholders who
have elected to receive hard copies by post.

The Company will hold its AGM at The Grange, 100 High Street, London, N14 6BN
on Thursday 25 September 2025 at 09.00am.

The Annual Report, Notice of AGM and Form of Proxy will be made available on
the Company's website at https://ecoanimalhealth.com/investors/
(https://ecoanimalhealth.com/investors/) .

-Ends-

 

Contacts

                                                                020 8447 8899

 ECO Animal Health Group plc

 David Hallas (Chief Executive Officer)

 Christopher Wilks (Chief Financial Officer)

 ICR Healthcare (Financial PR)                                  020 3709 5700

 Mary-Jane Elliott

 Jessica Hodgson

 Singer Capital Markets (Nominated Adviser & Joint Broker)      020 7496 3000

 Philip Davies

 Sam Butcher

 Investec (Joint Broker)                                        020 7597 5970

 Gary Clarence

 Lydia Zychowska

 Equity Development                                             020 7065 2692

 Hannah Crowe

 Matt Evans

 

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing
branded veterinary pharmaceuticals globally, with expertise in antibiotics and
vaccines for pigs and poultry. We have a maturing proprietary R&D
pipeline.

 

Headquartered in the UK, with global offices including R&D and
manufacturing, we have marketing authorisations in over 70 countries and
employ over 200 people worldwide.

 

Our lead product, Aivlosin(®) is a proprietary, patented medication which is
effective against both respiratory and intestinal diseases in pigs and
poultry.

 

Click here for more information: https://ecoanimalhealth.com
(https://ecoanimalhealth.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAPKFBQABKKPFB